Startups channel feed

Graphite founder takes drug to re­cent­ly-launched Ka­mau Ther­a­peu­tics for a sec­ond chance: #ASH23

Last year
Cell/Gene Tx

Ho­ba, a Dan­ish biotech from No­vo, rais­es $25M to crack in­to dif­fi­cult pain and hear­ing loss fields

Last year
Financing

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Last year
R&D
Cell/Gene Tx

Sam Wak­sal's ROCK2 biotech Gravi­ton hauls in $35M boost from Ena­vate

Last year
Financing

Scoop: Res­o­nance Med­i­cine, a pro­tease biotech from David Liu’s lab, shuts down

Last year
People

A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

Last year
Cell/Gene Tx

Sanofi forms drug dis­cov­ery pact with French start­up Aqemia en route to ‘AI at scale’ am­bi­tion

Last year
Deals
AI

Ex­clu­sive: San Diego biotech rais­es $11.7M to use cells as tar­get­ed de­liv­ery ves­sels for ge­net­ic med­i­cines

Last year
Financing

ARCH-al­lied AN Ven­ture Part­ners rais­es $200M to build biotechs out of re­search from Japan

Last year
Financing

Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug dis­cov­ery

Last year
Financing
China

Or­na Ther­a­peu­tics trims staff in ‘de­fen­sive re­duc­tion’ de­spite large fi­nanc­ing hauls

Last year
People
Cell/Gene Tx

Neu­ro start­up stock craters af­ter PhI­II study marred with ‘sig­nif­i­cant de­vi­a­tion’ from tri­al pro­to­col

Last year
R&D

Flag­ship opens hub, plants roots in the UK as gov­ern­ment aims to boost life sci­ence ecosys­tem

Last year
R&D

Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

Last year
Financing
R&D

Obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics files for IPO

Last year
Financing

Biotech’s IPO out­look for the rest of the year sours in wake of war, broad­er in­dus­try strug­gles

Last year
Financing

Q32 Bio to take Ho­mol­o­gy Med­i­cines’ Nas­daq spot to fund PhII tri­als in au­toim­mune, in­flam­ma­to­ry con­di­tions

Last year
Deals

Pri­ma­ry care start­up For­ward rais­es $100M to grow na­tion­al­ly with self-ser­vice ‘Care­Pods’

Last year
Health Tech

NMD Phar­ma se­cures €75M from in­sid­ers for three PhII tri­als in neu­ro­mus­cu­lar dis­or­ders

Last year
Financing

Mur­al On­col­o­gy spins out from Alk­er­mes with $275M and a lead im­munother­a­py pro­gram

Last year
Financing

Sanofi-backed T-Ther­a­peu­tics bags $59M in Se­ries A to un­lock po­ten­tial of TCR ther­a­peu­tics: #Jef­feries23

Last year
Financing

Eye­Bio dou­bles the size of its Se­ries A as an­ti-VEGF vet­er­ans seek new ways of treat­ing reti­nal dis­eases

Last year
Financing

MBrace Ther­a­peu­tics cap­i­tal­izes on ADC wave with $85M Se­ries B to en­ter the clin­ic this quar­ter

Last year
Financing

Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Last year
Financing
First page Previous page 22232425262728 Next page Last page
A service from the Financial Times